NCT06490484View on ClinicalTrials.gov

Efficacy and Safety of HSK16149 Capsule in Chinese Patients With Diabetic Peripheral Neuropathic Pain Who Had an Inadequate Response to Pregabalin

PHASE2RecruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

April 19, 2024

Primary Completion Date

July 12, 2024

Study Completion Date

July 14, 2024

Conditions
Diabetic Peripheral Neuropathic Pain
Interventions
DRUG

HSK16149 20mg BID

Drug: HSK16149 20mg BID HSK16149 20mg, orally twice a day; treatment period: 4 weeks fixed dose.

DRUG

Pregabalin 150mg BID

Drug: Pregabalin 150mg BID Pregabalin 150mg, orally twice a day; treatment period: 1 week titration and 3 weeks fixed dose.

Trial Locations (1)

310009

RECRUITING

The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou

All Listed Sponsors
lead

Haisco Pharmaceutical Group Co., Ltd.

INDUSTRY